Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AN OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF RIMEGEPANT 75 MG ODT FOR ACUTE TREATMENT OF MIGRAINE IN ADULT PARTICIPANTS IN INDIA WITH PREVIOUS INSUFFICIENT RESPONSE TO TRIPTANS

NCT07685769 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07685769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07685769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AN OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF RIMEGEPANT 75 MG ODT FOR ACUTE TREATMENT OF MIGRAINE IN ADULT PARTICIPANTS IN INDIA WITH PREVIOUS INSUFFICIENT RESPONSE TO TRIPTANS
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Recruiting
Start date
July 24, 2026
Completion date
January 4, 2028
Enrollment
60 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acute treatment of migraine